Journal
BIOTECHNOLOGY LETTERS
Volume 30, Issue 4, Pages 571-579Publisher
SPRINGER
DOI: 10.1007/s10529-007-9594-0
Keywords
antigen delivery; cholera vaccines; protein expression; vaccine development
Categories
Funding
- NIAID NIH HHS [R21 AI081039, SC1 AI104993] Funding Source: Medline
- NIGMS NIH HHS [S06 GM008248, S06 GM008248-20] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [SC1AI104993, R21AI081039] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The development of safe, immunogenic and protective cholera vaccine candidates makes possible their use as a versatile antigen delivery platform. Foreign antigens can be delivered to the immune system with cholera vaccines by expressing heterologous antigens in live attenuated vectors, as fusion proteins with cholera toxin subunits combined with inactivated Vibrio cholerae whole cells or by exposing them on the surface of V. cholerae ghosts. Progress in our understanding of the genes expressed by V. cholerae during infection creates unprecedented opportunities to develop an improved generation of vaccine vectors to induce immune protection against a broad range of pathogenic organisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available